Motomaru Masutani

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Transient increase in plasma brain (b‐type) natriuretic peptide after percutaneous transluminal coronary angioplasty

Jun Tateishi, Motomaru Masutani, Mitsumasa Ohyanagi et al. · Clinical Cardiology · 2000 · 171 citations · Full text

Medicine, Cardiology, Internal Medicine +11

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

OCT Assessment of Thin-Cap Fibroatheroma Distribution in Native Coronary Arteries

Kenichi Fujii, Daizo Kawasaki, Motomaru Masutani et al. · JACC. Cardiovascular imaging · 2010 · 94 citations

Medicine, Cardiology, Surgery +16